Your browser is no longer supported. Please, upgrade your browser.
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-0.96 Insider Own0.10% Shs Outstand154.87M Perf Week-8.74%
Market Cap901.16M Forward P/E- EPS next Y-0.89 Insider Trans118.97% Shs Float11.25M Perf Month-0.55%
Income-122.80M PEG- EPS next Q-0.25 Inst Own76.60% Short Float13.45% Perf Quarter10.59%
Sales3.20M P/S281.61 EPS this Y30.10% Inst Trans-8.26% Short Ratio1.02 Perf Half Y-31.44%
Book/sh2.20 P/B2.47 EPS next Y4.30% ROA-30.10% Target Price- Perf Year52.96%
Cash/sh2.22 P/C2.45 EPS next 5Y1.00% ROE-39.70% 52W Range2.00 - 13.40 Perf YTD0.74%
Dividend- P/FCF- EPS past 5Y-24.90% ROI-39.10% 52W High-59.85% Beta2.21
Dividend %- Quick Ratio10.20 Sales past 5Y-15.10% Gross Margin- 52W Low169.00% ATR0.49
Employees400 Current Ratio10.20 Sales Q/Q114.30% Oper. Margin- RSI (14)40.28 Volatility7.32% 8.39%
OptionableYes Debt/Eq0.00 EPS Q/Q15.30% Profit Margin- Rel Volume0.42 Prev Close5.43
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume1.48M Price5.38
Recom2.40 SMA20-13.02% SMA50-7.40% SMA200-24.96% Volume288,458 Change-0.92%
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Feb-25-21 07:30AM  
Feb-11-21 08:00AM  
Feb-06-21 01:03AM  
Dec-16-20 12:32PM  
Dec-07-20 11:32PM  
Nov-20-20 07:30AM  
Nov-19-20 09:00AM  
Nov-12-20 08:00AM  
Nov-09-20 03:18PM  
Nov-08-20 10:00AM  
Nov-06-20 11:01AM  
Nov-05-20 07:30AM  
Oct-22-20 08:00AM  
Oct-16-20 12:41PM  
Oct-15-20 04:40PM  
Oct-13-20 12:04PM  
Oct-09-20 06:18AM  
Aug-28-20 10:30AM  
Aug-11-20 12:00PM  
Aug-10-20 07:40AM  
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
Jun-01-20 09:39PM  
May-29-20 05:08PM  
May-19-20 07:02AM  
May-14-20 12:00PM  
May-12-20 08:00AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
Mar-20-20 10:40PM  
Mar-11-20 11:35AM  
Feb-29-20 08:31AM  
Feb-27-20 07:30AM  
Feb-24-20 03:15PM  
Feb-20-20 04:00PM  
Feb-18-20 08:00AM  
Feb-07-20 04:05PM  
Feb-05-20 11:30AM  
Feb-03-20 09:13AM  
Jan-24-20 04:30PM  
Jan-22-20 01:18PM  
Jan-21-20 04:08PM  
Jan-17-20 12:00PM  
Jan-15-20 08:22AM  
Jan-14-20 12:29PM  
Jan-13-20 08:30AM  
Dec-30-19 05:25AM  
Dec-16-19 05:45AM  
Dec-03-19 02:20PM  
Nov-17-19 11:40AM  
Nov-16-19 02:00AM  
Nov-06-19 07:30AM  
Nov-01-19 08:00AM  
Oct-31-19 01:52PM  
Oct-09-19 08:00AM  
Oct-01-19 08:00AM  
Sep-30-19 08:45AM  
Sep-16-19 06:41AM  
Sep-10-19 09:01AM  
Sep-09-19 08:00AM  
Aug-27-19 02:11PM  
Aug-16-19 11:23AM  
Aug-01-19 10:24PM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lunger JohnChief Patient Supply OfficerJan 19Sale5.674,35824,7087,346Jan 19 09:01 PM
Norry ElliotChief Medical OfficerJan 19Sale5.672,11111,9683,539Jan 19 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 19Sale5.679,87956,00913,529Jan 19 09:00 PM
Lunger JohnChief Patient Supply OfficerJan 12Sale6.151,0586,5091,767Jan 12 09:01 PM
Bertrand William C JRChief Operating OfficerJan 12Sale6.152,23413,7443,768Jan 12 09:01 PM
Rawcliffe AdrianChief Executive OfficerJan 12Sale6.152,70716,6543,695Jan 12 09:00 PM
Norry ElliotChief Medical OfficerJan 12Sale6.158415,1741,396Jan 12 09:00 PM
Bertrand William C JRChief Operating OfficerJan 04Sale5.333,49918,6425,864Jan 05 09:01 PM
Lunger JohnChief Patient Supply OfficerJan 04Sale5.331,0655,6741,760Jan 05 09:02 PM
Norry ElliotChief Medical OfficerJan 04Sale5.338454,5021,392Jan 05 09:00 PM
Rawcliffe AdrianChief Executive OfficerJan 04Sale5.334,96726,4646,737Jan 05 09:00 PM
Wood GavinChief Financial OfficerDec 14Buy0.6924,00016,55057,000Dec 16 09:00 PM
Bertrand William C JRChief Operating OfficerDec 14Buy0.69207,000143,824284,808Dec 15 09:00 PM
Rawcliffe AdrianChief Executive OfficerSep 01Sale8.512,77623,6373,076Sep 02 09:00 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerAug 03Sale8.74200,0001,748,1800Aug 04 09:02 PM
Lunger JohnChief Patient Supply OfficerAug 03Sale9.254,82344,6138,066Aug 04 09:02 PM
Rawcliffe AdrianChief Executive OfficerAug 03Sale9.252,78825,7893,064Aug 04 09:01 PM
Wood GavinChief Financial OfficerJun 29Buy1.6233,00053,46033,000Jun 30 09:01 PM
Alleva Lawrence MDirectorJun 09Buy1.8912,90024,38112,900Jun 11 09:00 PM
Noble JamesDirectorMay 29Sale9.33500,0004,666,0000Jun 02 09:30 PM